Chronic Psychological Stress Attenuates the Efficacy of anti-PD-L1 Immunotherapy for Bladder Cancer in Immunocompetent Mice

References

• Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104. doi:10.1016/j.eururo.2020.03.055.
   PubMed Web of Science ®Google Scholar
• Fernández MI, Brausi M, Clark PE, Cookson MS, Grossman HB, Khochikar M, et al. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol. 2019;37(1):3–13. doi:10.1007/s00345-018-2436-y.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Sylvester R. Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2014;66(1):55–56. doi:10.1016/j.eururo.2014.01.008.
   PubMed Web of Science ®Google Scholar
• Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, et al. Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(10):1240–1267. doi:10.6004/jnccn.2017.0156.
   PubMed Web of Science ®Google Scholar
• Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018;18(3):139–147. doi:10.1038/nrc.2017.117.
   PubMed Web of Science ®Google Scholar
• Choudhury NJ, Kiyotani K, Yap KL, Campanile A, Antic T, Yew PY, et al. Low T-cell receptor diversity, high somatic mutation burden, and high neoantigen load as predictors of clinical outcome in muscle-invasive bladder cancer. Eur Urol Focus. 2016;2(4):445–452. doi:10.1016/j.euf.2015.09.007.
   PubMedGoogle Scholar
• Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–339. doi:10.1038/nature12634.
   PubMed Web of Science ®Google Scholar
• Tripathi A, Plimack ER. Immunotherapy for urothelial carcinoma: current evidence and future directions. Curr Urol Rep. 2018;19(12):109. doi:10.1007/s11934-018-0851-7.
   PubMed Web of Science ®Google Scholar
• Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–122. doi:10.1016/S1470-2045(17)30065-7.
   PubMed Web of Science ®Google Scholar
• Vlachostergios PJ, Faltas BM. The molecular limitations of biomarker research in bladder cancer. World J Urol. 2019;37(5):837–848. doi:10.1007/s00345-018-2462-9.
   PubMed Web of Science ®Google Scholar
• Xie H, Li C, He Y, Griffin R, Ye Q, Li L. Chronic stress promotes oral cancer growth and angiogenesis with increased circulating catecholamine and glucocorticoid levels in a mouse model. Oral Oncol. 2015;51(11):991–997. doi:10.1016/j.oraloncology.2015.08.007.
   PubMed Web of Science ®Google Scholar
• Batty GD, Russ TC, Stamatakis E, Kivimaki M. Psychological distress in relation to site specific cancer mortality: pooling of unpublished data from 16 prospective cohort studies. BMJ. 2017;356:j108. doi:10.1136/bmj.j108.
   PubMed Web of Science ®Google Scholar
• Li M, Wang L. The associations of psychological stress with depressive and anxiety symptoms among Chinese bladder and renal cancer patients: the mediating role of resilience. PloS One. 2016;11(4):e0154729. doi:10.1371/journal.pone.0154729.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Ding W, Qian Z, Jiang G, Sun C, Xu K. Chronic unpredictable mild stress accelerates the growth of bladder cancer in a xenograft mouse model. Psychol Res Behav Manag. 2020;13:1289–1297. doi:10.2147/PRBM.S288983.
   PubMed Web of Science ®Google Scholar
• Elenkov IJ. Systemic stress-induced Th-2 shift and its clinical implications. Int Rev Neurobiol. 2002;52:163–186. doi:10.1016/s0074-7742(02)52009-2.
   PubMed Web of Science ®Google Scholar
• Glaser R, MacCallum RC, Laskowski BF, Malarkey WB, Sheridan JF, Kiecolt-Glaser JK. Evidence for a shift in the Th-1 to Th-2 cytokine response associated with chronic stress and aging. J Gerontol A Biol Sci Med Sci. 2001;56(8):M477–M482. doi:10.1093/gerona/56.8.m477.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. doi:10.1038/nature13954.
   PubMed Web of Science ®Google Scholar
• Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. JCO. 2018;36(28):2872–2878. doi:10.1200/JCO. 2018.79.0006.
   PubMed Web of Science ®Google Scholar
• Verheijden RJ, May AM, Blank CU, Aarts MJB, van den Berkmortel FWPJ, van den Eertwegh AJM, et al. Association of anti-TNF with decreased survival in steroid refractory Ipilimumab and anti-PD1-treated patients in the Dutch melanoma treatment registry. Clin Cancer Res. 2020;26(9):2268–2274. doi:10.1158/1078-0432.CCR-19-3322.
   PubMed Web of Science ®Google Scholar
• Yang H, Xia L, Chen J, Zhang S, Martin V, Li Q, et al. Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity. Nat Med. 2019;25(9):1428–1441. doi:10.1038/s41591-019-0566-4.
   PubMed Web of Science ®Google Scholar
• Vandeveer AJ, Fallon JK, Tighe R, Sabzevari H, Schlom J, Greiner JW. Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor. Cancer Immunol Res. 2016;4(5):452–462. doi:10.1158/2326-6066.CIR-15-0176.
   PubMed Web of Science ®Google Scholar
• Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, et al. ICUD-EAU international consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):45–57. doi:10.1016/j.eururo.2012.08.009.
   PubMed Web of Science ®Google Scholar
• Pitman A, Suleman S, Hyde N, Hodgkiss A. Depression and anxiety in patients with cancer. BMJ. 2018;361:k1415. doi:10.1136/bmj.k1415.
   PubMed Web of Science ®Google Scholar
• Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol. 2014;43(2):476–493. doi:10.1093/ije/dyu038.
   PubMed Web of Science ®Google Scholar
• Katz RJ, Hersh S. Amitriptyline and scopolamine in an animal model of depression. Neurosci Biobehav Rev. 1981;5(2):265–271. doi:10.1016/0149-7634(81)90008-7.
   PubMed Web of Science ®Google Scholar
• Ferreira MF, Castanheira L, Sebastiao AM, Telles-Correia D. Depression assessment in clinical trials and pre-clinical tests: a critical review. Curr Top Med Chem. 2018;18(19):1677–1703. doi:10.2174/1568026618666181115095920.
   PubMed Web of Science ®Google Scholar
• Eng JW, Kokolus KM, Reed CB, Hylander BL, Ma WW, Repasky EA. A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response. Cancer Immunol Immunother. 2014;63(11):1115–1128. doi:10.1007/s00262-014-1617-9.
   PubMed Web of Science ®Google Scholar
• Krizanova O, Babula P, Pacak K. Stress, catecholaminergic system and cancer. Stress. 2016;19(4):419–428. doi:10.1080/10253890.2016.1203415.
   PubMed Web of Science ®Google Scholar
• Powell ND, Tarr AJ, Sheridan JF. Psychosocial stress and inflammation in cancer. Brain Behav Immun. 2013;30 Suppl:S41–S47. doi:10.1016/j.bbi.2012.06.015.
   PubMed Web of Science ®Google Scholar
• Saul AN, Oberyszyn TM, Daugherty C, Kusewitt D, Jones S, Jewell S, et al. Chronic stress and susceptibility to skin cancer. J Natl Cancer Inst. 2005;97(23):1760–1767. doi:10.1093/jnci/dji401.
   PubMedGoogle Scholar
• Kalinichenko VV, Mokyr MB, Graf LJ, Cohen RL, Chambers DA. Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene expression. J Immunol. 1999;163(5):2492–2499.
   PubMed Web of Science ®Google Scholar
• Shi Y, Devadas S, Greeneltch KM, Yin D, Allan MR, Zhou JN. Stressed to death: implication of lymphocyte apoptosis for psychoneuroimmunology. Brain Behav Immun. 2003;17 Suppl 1 (Suppl 1):S18–S26. doi:10.1016/S0889-1591(02)00062-4.
   PubMedGoogle Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:10.1016/j.immuni.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 2016;44(6):1255–1269. doi:10.1016/j.immuni.2016.06.001.
   PubMed Web of Science ®Google Scholar
• Saito R, Smith CC, Utsumi T, Bixby LM, Kardos J, Wobker SE, et al. Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy. Cancer Res. 2018;78(14):3954–3968. doi:10.1158/0008-5472.CAN-18-0173.
   PubMed Web of Science ®Google Scholar
• Ngiow SF, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, et al. A threshold level of intratumor Cd8+ T-cell PD1 expression dictates therapeutic response to anti-PD1. Cancer Res. 2015;75(18):3800–3811. doi:10.1158/0008-5472.CAN-15-1082.
   PubMed Web of Science ®Google Scholar
• Luckheeram RV, Zhou R, Verma AD, Xia B. CD4(+) T-cells: differentiation and functions. Clin Dev Immunol. 2012;2012:925135. doi:10.1155/2012/925135.
   PubMedGoogle Scholar
• Tej G, Neogi K, Nayak PK. Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody. Int Immunopharmacol. 2019;77:106002. doi:10.1016/j.intimp.2019.106002.
   PubMed Web of Science ®Google Scholar
• Walker J, Hansen CH, Martin P, Symeonides S, Ramessur R, Murray G, et al. Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiat. 2014;1(5):343–350. doi:10.1016/S2215-0366(14)70313-X.
   PubMed Web of Science ®Google Scholar